These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19473616)

  • 1. Renal histology before and after effective enzyme replacement therapy in a patient with classical Fabry's disease.
    Hirashio S; Taguchi T; Naito T; Maki K; Ogata S; Taniyama K; Taniguchi Y; Yorioka N
    Clin Nephrol; 2009 May; 71(5):550-6. PubMed ID: 19473616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
    Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
    J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
    Mignani R; Cagnoli L
    J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
    Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
    Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of enzyme replacement therapy (ERT) on renal function of patients with Fabry's disease].
    Thomaidis T; Relle M; Reinke J; Beck M; Schwarting A
    Med Klin (Munich); 2009 Sep; 104(9):699-703. PubMed ID: 19779674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
    Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Enzyme replacement therapy in Fabry's disease].
    Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
    Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of replacement enzyme therapy on central nervous system manifestations in Fabry's disease].
    Besson G; Vadot W; Guellerin J
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S257-9. PubMed ID: 21211675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agalsidase benefits renal histology in young patients with Fabry disease.
    Tøndel C; Bostad L; Larsen KK; Hirth A; Vikse BE; Houge G; Svarstad E
    J Am Soc Nephrol; 2013 Jan; 24(1):137-48. PubMed ID: 23274955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry-like laminated myelin body associated with IgA nephropathy.
    Yoshida A; Morozumi K; Takeda A; Koyama K; Oikawa T
    Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1303-7. PubMed ID: 7853764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
    Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
    N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.
    Desnick RJ
    Expert Opin Biol Ther; 2004 Jul; 4(7):1167-76. PubMed ID: 15268683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravenous enzyme substitution therapy in children with Fabry's disease].
    Tøndel C; Laegreid LM; Hirth A; Houge G; Månsson JE; Søvik O
    Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3388-90. PubMed ID: 14713976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function.
    De Schoenmakere G; Chauveau D; Grünfeld JP
    Nephrol Dial Transplant; 2003 Jan; 18(1):33-5. PubMed ID: 12480957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deceased renal transplantation in patient with Fabry's disease maintained by enzyme replacement therapy.
    Kato T; Nishimura K; Ichikawa Y
    Int J Urol; 2009 Jul; 16(7):650. PubMed ID: 19659805
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzyme replacement therapy for Fabry's disease.
    Waldek S; Germain DP; Wanner C; Warnock DG
    Lancet; 2010 May; 375(9725):1523; author reply 1523-4. PubMed ID: 20435225
    [No Abstract]   [Full Text] [Related]  

  • 18. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
    del Toro N; Milán JA; Palma A
    Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
    [No Abstract]   [Full Text] [Related]  

  • 20. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
    Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
    G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.